GRAFTON, Wis., Feb. 11, 2014 /PRNewswire/ -- Cedarburg Hauser Pharmaceuticals (CHP), an experienced contract development and manufacturing organization (CDMO) specializing in small molecule APIs, has announced the hire Alex Tretyakov, Ph.D. as its Director of Process Development.
"In his 25 plus years of industry experience Alex has demonstrated a real ability to streamline processes and drive growth via scientific excellence," says CEO, Tony Laughrey. "We are counting on Dr. Tretyakov to help accelerate Cedarburg Hauser's growth and are excited to have him on board."
In his new role, Dr. Tretyakov will lead Cedarburg Hauser's process and analytical development groups. Dr. Tretyakov will also join CSO John Lynch in serving as the technical face of the company and infusing his unique insight into customer projects.
"Dr. Tretyakov has earned an excellent reputation in our industry by delivering on-time solutions with quality chemistry," says Chuck Boland, Executive Vice President. "These attributes are important as they ensure the success of a project and help establish Cedarburg Hauser as an industry leader."
Most recently, Dr. Tretyakov served as the Vice President of R&D at PCI Synthesis and previously held the same position at Cambridge Major Laboratories. Tretyakov holds a Ph.D. in organic chemistry from the University of Oklahoma, and completed his M.S. in organic chemistry and B.S. in Chemical Engineering at the Leningard Chemical Pharmaceutical Institute.
About Cedarburg Hauser Pharmaceuticals
Cedarburg Hauser Pharmaceuticals is an experienced, contract development and manufacturing organization (CDMO), specializing in small molecule active pharmaceutical ingredients (API) and pharmaceutical intermediates. Cedarburg Hauser leverages a talented group of scientists and supporting -staff, as well as a centralized approach to project management, to ensure on-time and on-budget completion of projects involving the development, scale-up, and manufacturing of complex APIs.
Bob Forner, Marketing Manager
Read more news on Cedarburg Hauser Pharmaceuticals.
SOURCE Cedarburg Hauser Pharmaceuticals